Vincent de Groot

picture speaker
Vice President, Antibody-Drug Conjugates, BioPharmaceuticals, Synthon

CV

Before joining Synthon, Dr. de Groot was one of the two founders of Syntarga B.V. and served as its CEO from 2001 2011, leading the company from inception to acquisition. Syntarga was acquired by Synthon in 2011. Dr. de Groot (M.Sc. Organic Chemistry; Radboud University Nijmegen, The Netherlands, University of Bologna, Italy, and University of Perugia, Italy) obtained his Ph.D. degree cum laude from the Radboud University Nijmegen (Department of Organic Chemistry). He published more than a dozen scientific papers and review articles in established journals and is inventor and (co-)author of several patents and patent applications. Dr. de Groot won several national and international awards and he has received the Certified Licensing Professional (CLP) credential from LES.

Summary

Preclinical Development Progress of ADCs based on Novel Potent Payload Linker-Drug Technology
- Optimizing unique linker chemistry complementary with duocarmycin chemistry yielding highly stable and potent ADCs
- ADC & payload stabilities in plasma, cleavage kinetics and in vivo therapeutic window aspects for ADCs
- Latest results of preclinical development progress, efficacy, safety, will be presented